Trending Tickers: $RVMD Trial Data, $BE Oracle Deal, $TEM Predicta Collaboration
This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
Revolution Medicines ($RVMD) Reports Positive Phase 3 Results for Pancreatic Cancer Drug
Revolution Medicines ($RVMD), a late-stage clinical oncology company developing targeted therapies for RAS-driven cancers, announced positive results from its Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic cancer.
According to the company, patients treated with daraxonrasib, taken as a daily oral pill, lived significantly longer compared to those receiving standard intravenous chemotherapy. The median overall survival was 13.2 months for daraxonrasib versus 6.7 months for chemotherapy, meaning the drug roughly doubled survival time in this patient group. The trial met all of its primary and key secondary endpoints, including both progression-free survival and overall survival.
Pancreatic cancer is one of the most difficult cancers to treat, with about 90% of tumors driven by mutations in a protein called RAS. Daraxonrasib is designed to block these RAS mutations across a broad range of variants, making it potentially relevant for the vast majority of pancreatic cancer patients. The company stated that daraxonrasib was generally well tolerated, with no new safety concerns.
Revolution Medicines said it plans to submit the data to global regulatory authorities, including the U.S. Food and Drug Administration, as part of a future approval application. The drug has already received Breakthrough Therapy Designation and Orphan Drug Designation from the FDA for previously treated metastatic pancreatic cancer. The company also intends to present detailed results at the 2026 American Society of Clinical Oncology Annual Meeting.
The company is currently running four Phase 3 trials for daraxonrasib across pancreatic and lung cancers, including a recently launched trial testing the drug as a first-line treatment for metastatic pancreatic cancer.
Stock Price Reaction
$RVMD shares surged approximately 38% following the announcement.
Bloom Energy ($BE) Expands Oracle Partnership
Bloom Energy ($BE), a power solutions company that manufactures solid oxide fuel cell systems for on-site electricity generation, announced an expanded partnership with Oracle to supply up to 2.8 gigawatts of fuel cell capacity for Oracle’s AI and cloud computing infrastructure.
Under the master services agreement, an initial 1.2 gigawatts of capacity has already been contracted, with deployment underway across Oracle projects in the United States. According to the company, Bloom’s fuel cells provide fast, reliable on-site power suited for AI workloads, which require the kind of rapid, load-following support that traditional power grids were not designed to deliver.
The expanded deal builds on the companies’ existing partnership. The company said it delivered a fully operational fuel cell system to Oracle last year in just 55 days, more than a month ahead of the anticipated 90-day deployment schedule. Bloom’s modular fuel cell systems can be installed significantly faster than traditional power solutions, helping customers accelerate their time-to-power and reduce project risk.
The agreement comes as data center developers increasingly turn to distributed, on-site power generation to meet surging electricity demand from AI infrastructure. Oracle, which has been investing heavily in its cloud buildout, intends to use Bloom’s fuel cells at facilities across the United States. On April 9, Bloom issued a warrant to Oracle on terms previously announced in October 2025.
Stock Price Reaction
$BE shares jumped approximately 15% in after-hours trading following the announcement, pushing the stock past $200 for the first time.
Tempus AI ($TEM) Expands Collaboration With Predicta on Blood Cancer Genome Test
Tempus AI ($TEM), a technology company using artificial intelligence to advance precision medicine, announced a commercial expansion of its collaboration with Predicta Biosciences to broaden access to GenoPredicta, a co-branded whole-genome sequencing assay for blood cancers and residual disease monitoring.
According to the company, the test combines flow cytometry, a method used to count and analyze cells, with whole-genome sequencing to provide a detailed genetic picture from peripheral blood or bone marrow samples. Tempus said the assay is highly sensitive, capable of detecting genetic changes from as few as 50 tumor cells, or roughly one in a million cells.
The companies positioned GenoPredicta as a single-workflow alternative to traditional testing, which typically requires several separate procedures. Because the test works equally well on blood samples as on bone marrow, it could also reduce the need for invasive bone marrow biopsies in some patients, according to the company.
Tempus said the assay is already available to its life sciences partners for use in exploratory research and clinical development. It has been clinically validated in multiple myeloma, a type of blood cancer, and certain related conditions, while remaining research-use only in other indications. Management framed the collaboration as a way to help pharmaceutical partners optimize clinical trials and advance personalized treatment approaches.
Stock Price Reaction
$TEM shares rose approximately 14% following the announcement.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
